HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) Income from Continuing Operations (2015 - 2021)

HUTCHMED (China)'s (HMDCF) quarterly Income from Continuing Operations came in at -$235.7 million in Q4 2021, down 238.27% quarter-over-quarter from $170.5 million in Q3 2021.

Analysis

HUTCHMED (China) (HMDCF) Income from Continuing Operations (2015 - 2021) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Income from Continuing Operations for 6 consecutive years, with -$235.7 million the latest figure, recorded in Q4 2021.

  • On a quarterly basis, Income from Continuing Operations changed N/A year-over-year to -$235.7 million in Q4 2021; TTM through Dec 2021 was -$203.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $562.3 million, up 9140.77% from the prior year.
  • Income from Continuing Operations was -$235.7 million for Q4 2021 at HUTCHMED (China), down from $170.5 million in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at $170.5 million in Q3 2021 and troughed at -$235.7 million in Q4 2021.
  • A 4-year average of -$23.8 million and a median of -$32.3 million in 2019 frame the typical range for Income from Continuing Operations.
  • The widest YoY moves for Income from Continuing Operations: up 250.63% in 2019, down 367.87% in 2019.
  • Over 4 years, Income from Continuing Operations stood at $22.1 million in 2018, then plunged by 270.87% to -$37.8 million in 2019, then slipped by 17.28% to -$44.3 million in 2020, then slumped by 432.37% to -$235.7 million in 2021.
  • The last three Income from Continuing Operations figures came in at -$235.7 million (Q4 2021), $170.5 million (Q3 2021), and -$77.6 million (Q2 2021), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Amgen 212.35 Bn 198.36 Bn 7.24 Bn 2.38 Bn
2 Gilead Sciences 181.19 Bn 178.01 Bn 6.22 Bn -10.50 Bn
3 Vertex Pharmaceuticals 132.48 Bn 124.62 Bn 2.84 Bn 1.10 Bn
4 Regeneron Pharmaceuticals 82.59 Bn 74.60 Bn 3.93 Bn 1.30 Bn
5 Argenx Se 61.45 Bn 56.27 Bn 1.37 Bn 601.00 Mn
6 Moderna 54.89 Bn 49.75 Bn 52.00 Mn -782.00 Mn
7 Alnylam Pharmaceuticals 34.21 Bn 30.90 Bn 992.69 Mn 164.49 Mn
8 Biogen 31.38 Bn 30.10 Bn 1.96 Bn 97.50 Mn
9 Roivant Sciences 29.81 Bn 29.81 Bn 1.16 Mn -290.61 Mn
10 HUTCHMED (China) 376.85 Mn 391.04 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 -235.70 Mn
Sep 28, 2021 170.46 Mn
Jun 30, 2021 -77.62 Mn
Mar 31, 2021 -60.97 Mn
Jun 30, 2020 -44.27 Mn
Mar 31, 2020 -30.28 Mn
Dec 31, 2019 -37.75 Mn
Sep 30, 2019 -34.24 Mn
Jun 30, 2019 -99.44 Mn
Mar 31, 2019 33.60 Mn
Dec 31, 2018 22.09 Mn
Sep 30, 2018 12.78 Mn
Jun 30, 2018 70.12 Mn
Mar 31, 2018 -22.31 Mn
Jun 30, 2016 29.56 Mn
Jun 30, 2015 23.49 Mn